Procf.Pk
PROCF.PK operates in the Pharmaceuticals industry, developing and commercializing prescription drugs and therapies to treat various medical conditions.
Business. PROCF.PK operates in the Pharmaceuticals industry, developing and commercializing prescription drugs and therapies to treat various medical conditions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PROCF.PK operates in the Pharmaceuticals industry, developing and commercializing prescription drugs and therapies to treat various medical conditions.
PROCF.PK's capital structure is highly leveraged, with total liabilities of $462.8 million and total equity of -$51.1 million, resulting in a debt-to-equity ratio of -6.0. The company's liquidity position is weak, as evidenced by a current ratio of 0.52, indicating that current assets are insufficient to cover current liabilities. Despite a net loss of $68.3 million, the company generated $88.4 million in operating cash flow, but free cash flow was negative at -$73.3 million, driven by capital expenditures of -$25.0 million.
Profitability metrics are mixed. The company reported a gross profit of $191.5 million, but operating income was negative at -$39.3 million, and net income was -$68.3 million. Return on equity is positive at 1.34, but return on assets is negative at -0.17, reflecting the company's high leverage and poor asset utilization. These results fall below the industry median for profitability, as the company is in a loss-making position despite generating revenue above the industry average.
Geographic and segment exposure is not disclosed in the available data, but the company's revenue concentration is likely high in its core pharmaceutical products. The lack of segment data prevents a detailed analysis of revenue diversification.
Growth trajectory is uncertain. Revenue for the latest period was $373.8 million, but the company is not disclosing forward-looking guidance. Analyst estimates suggest a recent actual revenue of $423.7 million, but no clear growth trend is evident from the data.
Risk factors include liquidity constraints and a negative net cash position after subtracting total debt. The company has a low dilution risk, with shares outstanding basic and diluted being equal at 2.33 billion, but the negative equity position increases the risk of further dilution in the event of additional financing. The company has not disclosed any recent equity offerings or dilutive events in the available data.
Recent events include the latest financial results, which show a net loss and negative free cash flow. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational performance.
- PROCF.PK is a pharmaceutical company with a negative net income and high leverage.
- The company's liquidity position is weak, with a current ratio of 0.52 and negative net cash after debt.
- Despite generating operating cash flow, the company's free cash flow is negative due to capital expenditures.
- Profitability metrics are mixed, with a positive return on equity but a negative return on assets.
- The company's growth trajectory is unclear, with no disclosed forward-looking guidance.
- Risk factors include liquidity constraints and a negative equity position.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- PROCF.PK Market data — financials · 2026-05-29
- Sofgen Pharma SA Market data — analyst estimates · 2026-05-29
Ownership & reference
Leadership
- Alejandro Kostia Nicolas Weinstein CrenovichExecutive Chairman of the Board